IDEXX Laboratories, Inc. $IDXX Holdings Raised by Public Employees Retirement Association of Colorado

Public Employees Retirement Association of Colorado grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 438.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 41,388 shares of the company’s stock after acquiring an additional 33,700 shares during the quarter. Public Employees Retirement Association of Colorado owned approximately 0.05% of IDEXX Laboratories worth $28,000,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in IDXX. Empowered Funds LLC boosted its position in IDEXX Laboratories by 6.6% during the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after purchasing an additional 95 shares during the period. Sivia Capital Partners LLC acquired a new position in IDEXX Laboratories during the 2nd quarter valued at approximately $265,000. Jump Financial LLC boosted its position in IDEXX Laboratories by 1,006.4% during the 2nd quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock valued at $2,967,000 after purchasing an additional 5,032 shares during the period. Cary Street Partners Financial LLC acquired a new position in IDEXX Laboratories during the 2nd quarter valued at approximately $164,000. Finally, Sei Investments Co. boosted its position in IDEXX Laboratories by 218.7% during the 2nd quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock valued at $64,678,000 after purchasing an additional 82,755 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $560.88 on Monday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. IDEXX Laboratories, Inc. has a 1 year low of $506.91 and a 1 year high of $769.98. The stock has a fifty day moving average of $563.06 and a two-hundred day moving average of $626.82. The firm has a market capitalization of $44.24 billion, a PE ratio of 41.30, a price-to-earnings-growth ratio of 3.07 and a beta of 1.56.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the previous year, the firm posted $2.91 EPS. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of analyst reports. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. UBS Group reduced their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday. Citigroup started coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective for the company. Finally, Stifel Nicolaus reduced their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.